AIFA publishes outcomes of 12–16 October CSE meeting
Italy's medicines agency has made available the results of the Scientific and Economic Committee's meeting, which covers reimbursement, pricing and classification matters.
The Italian Medicines Agency (AIFA) announced on 23 October 2026 that the outcomes of the Scientific and Economic Committee for Medicines (CSE) meeting, held from 12 to 16 October 2026, are now available.
The notice itself does not set out the decisions taken. It directs readers to a dedicated page on the AIFA website covering the meeting, which is reachable through the related links box on the announcement.
The CSE advises on reimbursement, pricing and classification decisions for medicines in Italy. Its outcomes are therefore chiefly of interest to market-access teams tracking product-level developments in the Italian market.
What it means for your team
- Market-access teams should consult the linked AIFA page on the 12–16 October 2026 meeting for product-specific outcomes, as the announcement gives no details.
- Companies with reimbursement, pricing or classification files before AIFA may wish to check whether their products were discussed at this meeting.
- Regulatory affairs teams should not infer any decisions from the notice alone; only the detailed meeting page contains the results.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial